alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
[Federal Register Volume 75, Number 38 (Friday, February 26, 2010)]
[Notices]
[Page 8977]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-3914]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Human Genome Research Institute; Notice of Closed 
Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: Center for Inherited Disease Research Access 
Committee.
    Date: March 12, 2010.
    Time: 2 p.m. to 3 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 5635 Fishers Lane, Suite 
4076, Bethesda, MD 20852. (Telephone Conference Call)
    Contact Person: Ken D. Nakamura, PhD, Scientific Review Officer, 
Scientific Review Branch, National Human Genome Research Institute, 
National Institutes of Health, 5635 Fishers Lane, Suite 4076, MSC 
9306, Rockville, MD 20852, 301-402-0838.

(Catalogue of Federal Domestic Assistance Program Nos. 93.172, Human 
Genome Research, National Institutes of Health, HHS)

    Dated: February 18, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2010-3914 Filed 2-25-10; 8:45 am]
BILLING CODE 4140-01-P
05/21/201 0 15;4 7 FAX 2024935142 FAA ^ DMS §1001/00 1 

JONES DAY 

2727 NORTH HARWOOD STREET ' DALIES, TEXAS 75201-151 5 

TELEPHONE: 21 4.-220-3939 • FACSIMILE. 21-d-deS-S 10O 

JP004207 

808817-600003 

April 27, 2010 

Direct Number; (214)969-5021 

eps I nger@jonesday com 

VIA FEDEX C ' l 

Federal Aviation AJniinistration 

Attn: Hearing Dockei Clerk. AGC-430 

800 Independence Avenue, SW 

Wilbur Wright Bldg., Suite 2W1000 

Washington, DC 20591 CS) 

Dear Sir or Madam: 

Re: Final Notice of Proposed Civil.PenaUy 

Case 20Q8SW210058 

Pursuant to 14 C.F.R. § 13.16, Respondent American Airlines, Inc., through the 

undersigned counsel, respectfully requests a hearing in the abovc-rclbrcneed civil penahy action 

All pleadings and court papers in this civil penalty action should be sent to: 

Evan P, Singer 

JONES DAY 

2727 North Harwood Street 

Dallas, lexas 75201 

Phone: (214)969-5021 

Facsimile: (214)969-5100 

cpsiniicri'i^fiionosdav.cotn 

Please feel free to give me a call if you have any quc.siion.s. 

Sincerely yours. 

Flvan P. Singer 

cc: Yolanda Ayala Bemal, F.sq. (By FedEx) 

Krancis C Hell, Esq. (By E-mail) 

I>1 !-C^l()2V74vl 

ATLANTA " aFl.lINC^ • URUSSEUS • CHICAGO - CLEVELAND - COLUMBUS • DALLAS - FRANKFURT • MONO KONC • HOUSTON 

IRVINE • LONDON • LOS ANCELES • HAORI C ' MILAN • MOSCOW • MUNICH - NEW DELHI - NEW YORK - PARIS - PITTSBURGH 

»AN DIEGO - SAN FH ANlCliir.O > SHANOMAI • SILICON VALLG V • SlNGAF'OPC > aTDNtV • lAII-'Ll ' I OKTO " WASiHINt-I ON
Editorial Note on Part 184
Editorial Note: Nomenclature changes to part 184 appear at 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 69 FR 13717, Mar. 24, 2004; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; and 81 FR 49897, July 29, 2016.

§ 184.1295 Ethyl formate. ( a ) Ethyl formate (C3H6O2, CAS Reg. No. 109-94-4) is also referred to as ethyl methanoate. It is an ester of formic acid and is prepared by esterification of formic acid with ethyl alcohol or by distillation of ethyl acetate and formic acid in the presence of concentrated sulfuric acid. Ethyl formate occurs naturally in some plant oils, fruits, and juices but does not occur naturally in the animal kingdom.
( b ) The ingredient meets the specifications of the “Food Chemicals Codex,” 3d Ed. (1981), p. 376, which is incorporated by reference. Copies may be obtained from the National Academy Press, 2101 Constitution Ave. NW., Washington, DC 20418, or may be examined at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, call 202-741-6030, or go to: *http://www.archives.gov/federal_register/code_of_federal_regulations/ibr_locations.html .*
( c ) The ingredient is used as a flavoring agent and adjuvant as defined in § 170.3(o)(12) of this chapter.
( d ) The ingredient is used in food at levels not to exceed good manufacturing practice in accordance with § 184.1(b)(1). Current good manufacturing practice results in a maximum level, as served, of 0.05 percent in baked goods as defined in § 170.3(n)(1) of this chapter; 0.04 percent in chewing gum as defined in § 170.3(n)(6), hard candy as defined in § 170.3(n)(25), and soft candy as defined in § 170.3(n)(38) of this chapter; 0.02 percent in frozen dairy desserts as defined in § 170.3(n)(20) of this chapter; 0.03 percent in gelatins, puddings, and fillings as defined in § 170.3(n)(22) of this chapter; and 0.01 percent in all other food categories.
( e ) Prior sanctions for ethyl formate different from the uses established in this section do not exist or have been waived.
[45 FR 22915, Apr. 4, 1980, as amended at 49 FR 5612, Feb. 14, 1984]
The exemption would allow the petitioner to operate the 3DR Iris+ (UAS) to conduct aerial 

photography and videography for real estate, homeowners, realtors, home builders, home 

contractors, and/or home inspectors for real estate marketing and inspections of home 

exteriors, surveying, marine photo and video, agriculture, and special events.

I petition the Federal Aviation Administration (FAA) for an exemption from part 21 subpart H, 

§§ 45.23(b), 45.29 61.113(a) and (b), 61.133, 61.23(a); 91.7(a),91.9(b)(2), 91.109, 91.119, 

91.121, 91.151(a), 91.203(a) and (b), 91.205(b), 91.215, 91.401–91.417 part 91 subpart E of 

Title 14, Code of Federal Regulations.

The petitioner also asks for an exemption from FAA Notice 8900.227 Unmanned Aircraft 

Systems (UAS) Operational

Approval, paragraphs 16(c)(4) and 16(e)(1).
<PAGE>

                                                                    EXHIBIT 11.1

          Computation of Pro Forma Net Income (Loss) Per Common Share
                     (in thousands, except per share data)
                                  (Unaudited)

<TABLE>
<CAPTION>
                                                      Years Ended
                                                      December 31,
                                         -----------------------------------
                                             1996         1995       1994
                                             ----         ----       ----
<S>                                      <C>           <C>         <C>
Pro forma net income (loss)              $ (19,238)    $  5,178    $ 1,783
                                         -----------------------------------
Weighted average number of
  common equivalent shares

   Common stock                             12,844       10,514      9,100
                                         -----------------------------------

   Dilutive effect of stock options              -          970        439
                                         -----------------------------------

   Pro forma weighted average
     shares outstanding                     12,844       11,484      9,539
                                         -----------------------------------

   Pro forma net income (loss)
     per share                           $   (1.50)    $   0.45    $  0.19
                                         ===================================
</TABLE>
§ 520.1510 Nitenpyram. ( a ) *Specifications.* Each tablet contains 11.4 or 57 milligrams (mg) nitenpyram.
( b ) *Sponsors.* See sponsor numbers in § 510.600(c) of this chapter: ( 1 ) No. 021091 for use as in paragraphs (d)(1)(i)(A), (d)(1)(ii)(A), and (d)(2) of this section.
( 2 ) No. 000061 for use as in paragraphs (d)(1)(i)(B) and (d)(1)(ii)(B) of this section.
( c ) *Special considerations.* The concurrent use of nitenpyram tablets and flavored milbemycin/lufenuron tablets as in paragraph (d)(1)(ii)(B) of this section shall be by or on the order of a licensed veterinarian.
( d ) *Conditions of use* — ( 1 ) *Dogs* — ( i ) *Amount.* ( A ) One 11.4-mg tablet for dogs weighing less than 25 pounds (lb) or one 57-mg tablet for dogs weighing more than 25 lb, as needed, for use as in paragraph (d)(1)(ii)(A) of this section.
( B ) One 11.4-mg tablet for dogs weighing less than 25 lb or one 57 mg tablet for dogs weighing more than 25 lbs, once or twice weekly, for use as in paragraph (d)(1)(ii)(B) of this section.
( ii ) *Indications for use.* ( A ) For the treatment of flea infestations on dogs and puppies 4 weeks of age and older and 2 lbs of body weight or greater.
( B ) The concurrent use of nitenpyram tablets as in paragraph (d)(1)(i)(B) of this section with either flavored lufenuron tablets as in § 520.1288(c)(1) of this chapter or flavored milbemycin and lufenuron tablets as in § 520.1443(d)(1) is indicated to kill adult fleas and prevent flea eggs from hatching.
( 2 ) *Cats* — ( i ) *Amount.* ( A ) One 11.4-mg tablet, as needed, for use as in paragraph (d)(2)(ii)(A) of this section.
( B ) One 11.4-mg tablet, once or twice weekly, for use as in paragraph (d)(2)(ii)(B) of this section.
( ii ) *Indications for use.* ( A ) For the treatment of flea infestations on cats and kittens 4 weeks of age and older and 2 lbs of body weight or greater.
( B ) The concurrent use of nitenpyram tablets as in paragraph (d)(2)(i)(B) of this section with flavored lufenuron tablets as in § 520.1288(c)(2) of this chapter is indicated to kill adult fleas and prevent flea eggs from hatching.
[68 FR 51906, Aug. 29, 2003, as amended at 80 FR 18776, Apr. 8, 2015; 86 FR 13184, Mar. 8, 2021; 86 FR 57997, Oct. 20, 2021]
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7417 Reported in Senate (RS)]

<DOC>

                                                       Calendar No. 541
118th CONGRESS
  2d Session
                                H. R. 7417

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                              June 4, 2024

     Received; read twice and referred to the Committee on Homeland 
                   Security and Governmental Affairs

                           September 25, 2024

               Reported by Mr. Peters, without amendment

_______________________________________________________________________

                                 AN ACT

 
 To designate the facility of the United States Postal Service located 
 at 135 West Spring Street in Titusville, Pennsylvania, as the ``Edwin 
                    L. Drake Post Office Building''.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. EDWIN L. DRAKE POST OFFICE BUILDING.

    (a) Designation.--The facility of the United States Postal Service 
located at 135 West Spring Street in Titusville, Pennsylvania, shall be 
known and designated as the ``Edwin L. Drake Post Office Building''.
    (b) References.--Any reference in a law, map, regulation, document, 
paper, or other record of the United States to the facility referred to 
in subsection (a) shall be deemed to be a reference to the ``Edwin L. 
Drake Post Office Building''.
                                                       Calendar No. 541

118th CONGRESS

  2d Session

                               H. R. 7417

_______________________________________________________________________

                                 AN ACT

 To designate the facility of the United States Postal Service located 
 at 135 West Spring Street in Titusville, Pennsylvania, as the ``Edwin 
                    L. Drake Post Office Building''.

_______________________________________________________________________

                           September 25, 2024

                       Reported without amendment
```
§ 556.347 Lasalocid. ( a ) *Acceptable daily intake (ADI).* The ADI for total residue of lasalocid is 10 μg/kg of body weight per day.
( b ) *Tolerances.* The tolerances for lasalocid (marker residue) are: ( 1 ) *Cattle.* Liver (target tissue): 0.7 ppm.
( 2 ) *Chickens.* ( i ) Skin with adhering fat (target tissue): 1.2 ppm.
( ii ) Liver: 0.4 ppm.
( 3 ) *Rabbits.* Liver (target tissue): 0.7 ppm.
( 4 ) *Sheep.* Liver (target tissue): 1.0 ppm.
( 5 ) *Turkeys.* ( i ) Liver (target tissue): 0.4 ppm.
( ii ) Skin with adhering fat: 0.4 ppm.
( c ) *Related conditions of use.* See § 558.311 of this chapter.
Exhibit 99.4

 

 
| **** |  | **Ernst & Young LLP**220  South Sixth Street, Ste 1400  Minneapolis, MN 55402-4509 |  | Phone:  (612) 343-1000  www.ey.com |
|------|--|----------------------------------------------------------------------------------------|--|------------------------------------|

 

 

Report of IndependentAccountants

 

 

Target National Bank (formerlyRetailers National Bank),Its Officers and DirectorsAs Servicer

 

We have examined management’sassertion, included in the accompanying report, Report of Management onCompliance, dated January 21, 2005, that Target National Bank (the Bank), asServicer, complied in all material respects with the administration andservicing requirements of Article III, Article IV, and Section 8.8 of theAmended and Restated Pooling and Servicing Agreement, dated as of April 28,2000, and the applicable provisions of the Series 2001-1 Supplement, dated asof August 22, 2001, and the Series 2002-1 Supplement, dated as of July 2, 2002,to the Target Credit Card Master Trust, as set forth in Exhibit A to theaccompanying Report of Management on Compliance as of January 1, 2005, and forthe fiscal year then ended. The Bank’s management is responsible for theassertion. Our responsibility is to express an opinion on the assertion basedon our examination.

 

Our examination was conductedin accordance with attestation standards established by the American Instituteof Certified Public Accountants and, accordingly, included examining, on a testbasis, evidence supporting management’s assertion and performing such otherprocedures as we considered necessary in the circumstances. We believe that ourexamination provides a reasonable basis for our opinion.

 

In our opinion, management’ sassertion referred to above is fairly stated, in all material respects.

 

 

January 21, 2005

 

 

A Member Practice of Ernst& Young Global
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.
      ( print page 9421)    
*Name of Committee:*                         National Institute on Drug Abuse Special Emphasis Panel Web-Enabled Cognitive/Neuropsychological Evaluation System (4411).                    

*Date:*                         March 30, 2010.                    

*Time:*                         1:30 p.m. to 3:30 p.m.                    

*Agenda:*                         To review and evaluate contract proposals.                    

*Place:*                         National Institutes of Health, 6101 Executive Boulevard, Rockville, MD 20852. (Telephone Conference Call.)                    

*Contact Person:*                         Lyle Furr, Contract Review Specialist, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Boulevard, Bethesda, MD 20892-8401. (301) 435-1439.                         *lf33c.nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS)

Dated: February 19, 2010.

Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2010-4032 Filed 3-1-10; 8:45 am]

BILLING CODE 4140-01-M
<PAGE>   1

EXHIBIT 10.3                   AMENDMENT AGREEMENT

THIS AGREEMENT is dated for reference the 7th day of December, 1998

AMONG:

                ACCEL FINANCIAL GROUP LTD., a corporation incorporated under the
                laws of Alberta

                (the "Corporation")

AND:

                802685 ALBERTA LTD., a corporation incorporated under the laws
                of Alberta

                ("Holdco")

AND:

                T&W FINANCIAL SERVICES COMPANY L.L.C., a limited liability
                company incorporated under the laws of the State of Washington

                ("T&W")

WHEREAS:

(A)     The parties hereto are parties to an amalgamation agreement (the
"Amalgamation Agreement") dated the 6th day of November, 1998; and

(B)     The parties wish to enter into this Agreement to amend the Amalgamation
Agreement in order to make effective certain amendments that they have agreed
to.

THEREFORE THIS AGREEMENT WITNESSES that the parties agree as follows:

1.      The Amalgamation Agreement is hereby amended by deleting the existing
definition of "Effective Date" in Section 1 and replacing it with the following
provision:

        ""Effective Date" means the date shown on the certificate of
        amalgamation to be issued in respect of the Amalgamation which will be
        February 15, 1999 or such earlier date on which all conditions precedent
        to the Amalgamation have been satisfied or waived;"

2.      The Amalgamation Agreement is hereby amended by deleting Section 18(g)
and replacing it


<PAGE>   2
                                     - 2 -


with the following provision:

        "(g)    on or before January 31, 1999, Holdco secures a firm financing
        commitment sufficient to permit it to complete the Amalgamation, such
        commitment to be on terms and conditions satisfactory to Holdco, acting
        reasonably;"

3.      The Amalgamation Agreement is hereby amended by deleting Section 18(h)
and replacing it with the following provision:

        "(h)    on or before January 31, 1999 Holdco will provide the
        Corporation with evidence satisfactory to the Corporation, acting
        reasonably, of Holdco's ability to meet the condition described in
        Section (i); and"

4.      The amendments described in Section 1,Section 2 and Section 3 above,
will have the same force and effect as if originally contained in the
Amalgamation Agreement.

5.      In all other respects the terms and conditions of the Amalgamation
Agreement are hereby confirmed as being in full force and effect.

IN WITNESS WHEREOF the parties have caused this agreement to be executed as of
the date first above written.

ACCEL FINANCIAL GROUP LTD.

By: BJ Buan
   ---------------------------------
   Name

802685 ALBERTA LTD.

By: Paul B. Luke
   ---------------------------------
    Name


<PAGE>   3
                                     - 3 -


T&W FINANCIAL SERVICES COMPANY, L.L.C.

By: Paul B. Luke
   ---------------------------------
    Name
§ 526.464 Cloxacillin benzathine. ( a ) *Specifications.* Each single-dose, 7.5- or 10-milliliter syringe contains cloxacillin benzathine equivalent to 500 milligrams (mg) cloxacillin.
( b ) *Sponsor.* See No. 000010 in § 510.600(c) of this chapter.
( c ) *Related tolerances.* See § 556.165 of this chapter.
( d ) *Conditions of use in dry cows* — ( 1 ) Amount . Infuse the contents of one syringe (equivalent to 500 mg cloxacillin) into each quarter immediately after last milking, but no later than 30 days before calving.
( 2 ) *Indications for use.* For the treatment of mastitis caused by *Staphylococcus aureus* and *Streptococcus agalactiae* including penicillin resistant strains in dairy cows during the dry period.
( 3 ) *Limitations.* Animals infused with this product must not be slaughtered for food until 30 days after the latest infusion. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[86 FR 13186, Mar. 8, 2021]